Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Trading 12-19 10:05:26 EST

1.85

-0.22

-10.87%

High2.08	Low1.83	Vol1.62M
Open2.05	D1 Closing2.07	Amplitude11.90%
Mkt Cap81.95M	Tradable Cap44.93M	Total Shares44.42M
T/O3.09M	T/O Rate6.65%	Tradable Shares24.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":1.845,"timestamp":1766156723398,"preClose":2.07,"halted":0,"volume":1619172,"delay":0,"floatShares":24350594,"shares":44419529,"eps":-1.501597,"marketStatus":"Trading","change":-0.225,"latestTime":"12-19 10:05:26 EST","open":2.05,"high":2.0763,"low":1.83,"amount":3089925.0273780003,"amplitude":0.118986,"askPrice":1.85,"askSize":2200,"bidPrice":1.83,"bidSize":2601,"shortable":0,"etf":0,"ttmEps":-1.501597,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766178000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.07,"preHourTrading":{"tag":"盘前","latestPrice":2.0324,"preClose":2.07,"latestTime":"09:27 EST","volume":61909,"amount":127138.70589649999,"timestamp":1766154422276},"postHourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.07,"latestTime":"19:59 EST","volume":38191,"amount":79375.4485,"timestamp":1766105967778},"volumeRatio":4.711585,"impliedVol":4.4875,"impliedVolPercentile":0.908},"requestUrl":"/m/hq/s/OTLK/tweets","defaultTab":"tweets","newsList":[{"id":"2592162529","title":"BRIEF-Outlook Therapeutics FY EPS USD -1.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162529","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592162529?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:05","pubTimestamp":1766149545,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics FY EPS USD -1.79\n\n\nDec 19 (Reuters) - Outlook Therapeutics FY net income USD -62.4 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nPLX192CCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2592625211","title":"Outlook Therapeutics FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2592625211","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592625211?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:05","pubTimestamp":1766149517,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. reported financial results for the full year ended September 30, 2025. The company recorded revenue of USD 1.4 million for the period. Net loss attributable to common stockholders was USD 62.4 million, or USD 1.79 per basic and diluted share. As of September 30, 2025, cash and cash equivalents stood at USD 8.1 million. Gross profit for the year was negatively affected by increased reserves for short-dated inventory included in original shipments to the UK in June 2025. Overall expenses for the fiscal year were USD 4.6 million lower than the previous year, primarily due to a reduction in research and development expenses following the completion of the NORSE Eight clinical trial in fiscal 2024. This decrease was partially offset by higher selling, general, and administrative expenses related to the launch of LYTENAVA in Europe in June 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLc4fhc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","SG9999014021.USD","BK4588","BK4139","LU0314104364.USD","SG9999014039.USD","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","OTLK","LU2210149790.SGD","BK4112"],"gpt_icon":0},{"id":"2592162582","title":"Outlook Therapeutics FY Net Income USD -62.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592162582?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:05","pubTimestamp":1766149500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nPLX192CCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2592617162","title":"Press Release: Outlook Therapeutics Reports Financial Results for Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2592617162","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592617162?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:05","pubTimestamp":1766149500,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., Dec. 19, 2025  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025.\"Over the course of fiscal year 2025, our team has worked diligently to position Outlook Therapeutics for success. We are preparing now for potential approval and progressing commercial launch activities in the U.S., as we await a decision from the FDA in just a few short weeks,\" commented Bob Jahr, Chief Executive Officer of Outlook Therapeutics. \"In Europe, our initial shipments of inventory are being used to prime and prepare to grow the market. Commercial activities remain ongoing as we push ahead with our efforts to expand into the next wave of country launches, including Austria and the Netherlands. Outside the U.S., we continue to identify potential partners for additional expansion. As we","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2264538146.SGD","LU0390134368.USD","LU0979878070.USD","LU0127658192.USD","IE0004445239.USD","BK4585","BK4543","LU1988902786.USD","LU2355687059.USD","BK4141","LU0056508442.USD","LU1242518857.USD","BK4529","LU1064131342.USD","BK4554","LU0109392836.USD","LU0274383776.USD","LU0642271901.SGD","LU0823421416.USD","LU0823434740.USD","LU1861559042.SGD","LU1880398554.USD","LU1316542783.SGD","LU0889565833.HKD","LU0719512351.SGD","03160","LU0823421333.USD","BK4534","BK4604","LU1852331112.SGD","LU1923623000.USD","LU2054465674.USD","LU2098885051.SGD","BK4575","IE0009356076.USD","LU1951200564.SGD","LU2089985449.USD","LU2250418816.HKD","IE00B5949003.HKD","IE00BMPRXR70.SGD","LU2458330169.SGD","LU0823434583.USD","LU0198837287.USD","BK4512","LU2931357623.SGD","LU1880398471.USD","LU0082616367.USD","BK4588","LU1803068979.SGD","BK4612","OTLK","LU0081259029.USD","BK4614","LU2360106780.USD","BK4573","BK4532","LU1989764664.SGD","BK4555","BK4566","LU1951198990.SGD","BK4139","IE00BMPRXN33.USD","LU2458330243.SGD","BK4539","LU1303367103.USD","LU1242518931.SGD","BK4099","LU1861558580.USD","BK4605"],"gpt_icon":0},{"id":"2592969977","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2592969977","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592969977?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:00","pubTimestamp":1766055600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.FactSet Research Syss Inc.                       1Q      4.36   6:00 AM. Innovative Solutions and Support Inc.           4Q       .11       BMO. NIKE Inc. Class B                                2Q       .37   4:15 PM. Lamb Weston Hldgs Inc.                            2Q       .64   8:30 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0052756011.USD","WGO","BK4566","BIRK","DRI","BK4146","LU0310800965.SGD","FDX","LU0786609619.USD","LU0154245756.USD","FCEL","LU0868494708.USD","LU0545039389.USD","LW","NNE","BK4212","BK4112","DRUG","NKE","ISSC","LU1823568750.SGD","BK4547","BK4534","LU1366333091.USD","OTLK","BK4561","IE00BJJMRY28.SGD","LU1989772923.USD","CUK","BK4524","CTAS","LU0823417737.USD","HEI.A","PAYX","CAG","LU2506951875.HKD","KMX","ACN","IE00BVYPNV92.GBP","IE00BYQQ9H92.USD","KBH","LU1228905037.USD","LU2506951958.HKD","LU2506952097.USD","HEI","LU0823417653.USD","FDS","IE00BFXG0V08.USD"],"gpt_icon":1},{"id":"2591648985","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648985","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591648985?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:00","pubTimestamp":1765796400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Enerpac Tool Grp Corp Class A                   1Q       .37       AMC. FactSet Research Syss Inc.                       1Q      4.36   6:00 AM. Innovative Solutions and Support Inc.           4Q       .11       BMO. NIKE Inc. Class B                                2Q       .38   4:15 PM. Lamb Weston Hldgs Inc.                            2Q       .64   8:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEN","DRUG","WGO","ACN","ISSC","AMCDD","BK4567","HEI","NAVN","IE00BSNM7G36.USD","ABM","MU","NKE","BIRK","BK4152","SG9999004303.SGD","LU1235294995.USD","LEN.B","VERU","CAG","CTAS","BK4131","KMX","EPAC","BK4209","FDX","BK4553","LW","LU0323240290.USD","JBL","MLKN","LU1046421795.USD","AMC","LU0950375773.USD","BK4130","KBH","HEI.A","TTC","CUK","GIS","OGI","LEN/WD","FCEL","DRI","IE00BJJMRX11.SGD","WOR","PAYX","OTLK","LU0056508442.USD","FDS"],"gpt_icon":1},{"id":"2583680037","title":"H.C. Wainwright Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680037?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:39","pubTimestamp":1763163566,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on Outlook Therapeutics, with a price target of $1.00. Accor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-hold-rating-for-outlook-therapeutics-otlk-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-hold-rating-for-outlook-therapeutics-otlk-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OTLK"],"gpt_icon":0},{"id":"2583593112","title":"Outlook Therapeutics announces acceptance of BLA for ONS-5010","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593112","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593112?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:35","pubTimestamp":1763040944,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that the U.S. Food and Drug Administration, FDA, has acknowledged receipt of the resubmission of the Biologic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-announces-acceptance-of-bla-for-ons-5010-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-announces-acceptance-of-bla-for-ons-5010-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","OTLK","BK4007"],"gpt_icon":0},{"id":"2583593378","title":"Outlook Therapeutics Inc - FDA Sets Pdufa Goal Date of December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593378?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5XQJTH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2583593302","title":"Outlook Therapeutics Inc:  Ons-5010, IF Approved, Will Be Branded as Lytenava for Treatment of Wet Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593302?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5XQJTH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2580215062","title":"Outlook Therapeutics Inc - IF Approved, Ons-5010 to Be Branded as Lytenava for Wet Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2580215062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580215062?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:35","pubTimestamp":1762176900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUABZCKPP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2571510354","title":"Outlook Therapeutics Plans to Resubmit ONS-5010 Biologics License Application Before Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2571510354","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571510354?lang=en_us&edition=fundamental","pubTime":"2025-09-30 02:33","pubTimestamp":1759170784,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) said Monday it expects to resubmit its biologics license application for ONS-5010, an investigational treatment for wet macular degeneration, after completing a Type A meet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK4139","BK4539","OTLK"],"gpt_icon":0},{"id":"2571339031","title":"BRIEF-Outlook Therapeutics Provides Update On Type A Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2571339031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571339031?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:21","pubTimestamp":1759152072,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Provides Update On Type A Meeting With FDASept 29 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS PROVIDES UPDATE ON TYPE A MEETING WITH FDAOUTLOOK THERAPEU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA6DZRJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2571533522","title":"Outlook Therapeutics Provides Update on Type a Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2571533522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571533522?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:45","pubTimestamp":1759149900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA6DZRJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2571433577","title":"Outlook Therapeutics Inc - to Resubmit Bla by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571433577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571433577?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:45","pubTimestamp":1759149900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA6DZRJP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2569420436","title":"U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2569420436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569420436?lang=en_us&edition=fundamental","pubTime":"2025-09-22 15:58","pubTimestamp":1758527890,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, TeslaSept 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apple, GE Aerosp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nL5N3V90BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0444973449.USD","AAPL","LU1974910355.USD","NDRA","LU0642271901.SGD","TSLA","LU0210533765.USD","LU0345770993.USD","WEC","LU0072462426.USD","MTN","BK4576","LU0868494617.USD","LU2361044949.HKD","IE00B3SWFQ91.USD","JSPR","GB00BDT5M118.USD","LU1674673428.USD","LU2381873111.SGD","BK4505","MACW.SI","SG9999014880.SGD","GRI","LU0203201768.USD","LU0096364046.USD","BK4543","LU1084165304.USD","IE00BZ1G4Q59.USD","LU0316494557.USD","IE0009356076.USD","SG9999015986.USD","CRC","TSYW.SI","LU0127658192.USD","LU1003077747.HKD","IRM","GE","LU0251132253.USD","LU0215105999.USD","LU2191332357.HKD","RBLX","URI","LU1861215975.USD","LEN","LU0048584097.USD","SG9999002224.SGD","OTLK","SINT"],"gpt_icon":1},{"id":"2569272296","title":"Outlook Therapeutics Inc : Ascendiant Capital Markets Cuts Target Price to $8 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2569272296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569272296?lang=en_us&edition=fundamental","pubTime":"2025-09-22 10:45","pubTimestamp":1758509101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nFWN3V70RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2565595186","title":"Outlook Therapeutics Announces Departure of Chief Commercial Officer Jeff Evanson","url":"https://stock-news.laohu8.com/highlight/detail?id=2565595186","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565595186?lang=en_us&edition=fundamental","pubTime":"2025-09-06 05:01","pubTimestamp":1757106105,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. announced that Jeff Evanson has stepped down as the Chief Commercial Officer, effective September 5, 2025. His departure is classified as a termination of employment without cause.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL1v9HJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2564812773","title":"BRIEF-Outlook Therapeutics Requests Type A Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2564812773","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564812773?lang=en_us&edition=fundamental","pubTime":"2025-09-03 00:58","pubTimestamp":1756832291,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Requests Type A Meeting With FDAOutlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS REQUESTS TYPE A MEETING WITH FDAOUTLOOK THERAPEUTICS INC: TYPE A MEETING REQUEST HAS BEE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3TCWBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2564807818","title":"Outlook Therapeutics Requests Type a Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2564807818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564807818?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:35","pubTimestamp":1756816500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3TCWBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.035},{"period":"1month","weight":0.0838},{"period":"3month","weight":1.1495},{"period":"6month","weight":0.2141},{"period":"1year","weight":0.4786},{"period":"ytd","weight":0.0952}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.117155},{"month":2,"riseRate":0.444444,"avgChangeRate":0.160578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.049534},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.10242},{"month":5,"riseRate":0.666667,"avgChangeRate":0.154179},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.4,"avgChangeRate":-0.079775}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}